Immunohistochemical study of rat renal interstitial fibrosis induced by repeated injection of cisplatin, with special reference to the kinetics of macrophages and myofibroblasts.
Progressive renal interstitial fibrosis occurs following tissue injury, resulting in chronic renal failure. In the fibrogenesis, macrophages are speculated to induce myofibroblasts producing matrix protein. The kinetics of these cells in renal fibrosis induced in rats by repeated injection of cisplatin (CDDP) (2 mg/kg body weight, once weekly) was investigated immunohistochemically. During the 10-wk injection period, epithelial damage of the proximal renal tubules in the corticomedullary junction was seen, followed by cystic dilation of the affected tubules. During the 8-wk recovery period following the seventh injection, the size of the dilated lumina was diminished and atrophic tubules lined by regenerating epithelial cells appeared. Morphometrical analysis revealed that fibrosis began to develop around the dilated renal tubules in the injection period and was more advanced in the following recovery period. Coinciding with development of fibrotic tissues, the number of alpha-smooth muscle actin-positive myofibroblasts was significantly increased in the areas compared to that of controls. In the injection period, despite a significant increase in myofibroblast number, an elevation of ED-1 (primary antibody)-positive macrophage number was not observed. In the recovery period, however, a significant elevation of macrophage number was noticed in markedly advanced interstitial fibrosis. This suggests that rapid expansion of the macrophage population, probably resulting from release from myelosuppression due to CDDP, might contribute in part to development of myofibroblasts, leading to the augmented fibrosis in the recovery period.
Yamate
J
J
Department of Veterinary Pathology, College of Agriculture, University of Osaka Prefecture, Japan.
Ishida
A
A
Tsujino
K
K
Tatsumi
M
M
Nakatsuji
S
S
Kuwamura
M
M
Kotani
T
T
Sakuma
S
S
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000473:pathology; D000510:Alpha-Globulins; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D001973:Bromodeoxyuridine; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000633:toxicity*; D005347:Fibroblasts / Q000187:drug effects; D005355:Fibrosis / Q000139:chemically induced* / Q000473:pathology; D007150:Immunohistochemistry; D007700:Kinetics; D008264:Macrophages / Q000187:drug effects*; D008297:Male; D008854:Microscopy, Electron; D009395:Nephritis, Interstitial / Q000139:chemically induced* / Q000473:pathology; D051381:Rats; D011916:Rats, Inbred F344; D014746:Vimentin
D000510:Alpha-Globulins; D000970:Antineoplastic Agents; D014746:Vimentin; C013803:alpha 2u globulin; D001973:Bromodeoxyuridine; D002945:Cisplatin